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THE EFFECTS OF METFORMIN ON IMMUNE CELL FUNCTION IN 
PREDIABETIC PATIENTS 
LEAH BETH PERSKY 
ABSTRACT 
Objective 
T2D is a metabolic disease that is a significant health problem throughout many 
populations. Increased incidence of T2D across the age spectrum makes preventive 
measures for this disease a top healthcare priority. Physiological changes such as 
expression of pro-inflammatory T cell cytokines, insulin resistance, and pancreatic beta 
cell dysfunction play major roles in the onset of T2D.  Current treatments include 
lifestyle changes with oral medications and/or synthetic insulin therapy. While treatments 
aim to normalize blood glucose and increase insulin sensitivity in patients diagnosed with 
T2D, efforts are growing to find preventative therapies for prediabetes, a condition where 
blood glucose levels are higher than normal but are under the threshold determined for a 
diabetes diagnosis.  
 Metformin, a well-known first-line recommendation for treating T2D, in conjunction 
with lifestyle modification may be a viable preventative measure to delay the onset of 
T2D. Previous study results have created momentum to generate data promoting 
metformin use as an off-label preventative drug for T2D. To identify a therapeutic 
intervention that may help to shift T cell cytokine profiles from being pro-inflammatory 
and diabetogenic to anti-inflammatory, we investigated the effects of metformin on 
immune cell function in prediabetic patients. It is known that one effect of metformin is 
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activating AMPK, which secondarily decreases inflammation. We therefore hypothesized 
metformin affects immune cell function by modulating genes in the AMPK pathway.  
 Methods 
We recruited 49 subjects using EPIC database to screen patients with appointments at the 
Nutrition and Weight Management Center at Boston Medical Center. Forty-nine pre-
metformin and 13 post- metformin blood samples were collected from subjects at 
baseline and after three months of taking metformin, respectively. Ficoll was utilized to 
separate and extract PBMCs. I activated PBMCs with LPS or CpG for 24 hours, and anti-
CD3/CD28 for 24 or 40 hours. Then I isolated and reverse transcribed RNA, producing 
cDNA. We ran a human AMPK signaling qRT-PCR array on the 40-hour anti-
CD3/CD28 activated PBMCs from 4 randomly chosen subjects and analyzed data to 
investigate candidate targets in the AMPK pathway possibly modulated by metformin. I 
designed primers for six chosen targets and ran qRT-PCR comparing the pre- and post-
metformin dataset of 13 subjects, using the generated human gene-specific primers to see 
if these genes were affected across the dataset.  
 Results 
Total sample population was n=13. The majority of subjects were African American 
females. The study participants were considered prediabetic when A1C measured 
between 5.7-6.4%. Median A1C and BMI averaged at 5.8% and 38.6 kg/m2  2.48 (mean 
 SEM), respectively. There was an expected decrease in BMI as metformin is associated 
with weight loss. To understand how metformin may affect genes in the AMPK pathway, 
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qRT-PCR array analysis of the 40-hour anti-CD3/CD28 activated PBMCs in a subset of 4 
subjects was used to create a volcano plot. The plot demonstrated that out of the possible 
gene candidates, SLC2A4, LIPE, INSR, CRY1, GAPDH, and STK11 had the greatest log2 
fold change and –log (p-value). Further analysis on the 4 subjects compared delta Ct 
values and relative gene expression showing CRY1, a circadian function gene, had a 
significant decrease in expression (p=0.03, n=4, paired t-test). Primers were designed for 
the six candidate genes and used to run qRT-PCR on the entire dataset of 13 subjects. 
There was a significant decrease in expression of STK11 in 24-hour non-stimulated 
PBMCs (p=0.008, n=12, paired t-test) and CRY1 in 24-hour anti-CD3/CD28 activated 
PBMCs (p=0.04, n=12, paired t-test). There was a significant increase in expression of 
SLC2A4 in 24-hour CpG activated PBMCs (p=0.02, n=12, paired t-test). Furthermore, 
GLUT4 was detected in CpG activated immune cells and gene expression was increased 
in cells from subjects post-metformin treatment. 
 Conclusions 
Further investigation is required to examine how metformin decreases the expression of 
CRY1 and how this decrease associates with pro-inflammatory cytokine expression. 
STK11 expression was decreased in non-stimulated cells but did not show any trend in 
the activated conditions. Additional research is warranted to see if these results can be 
repeated, and if so, more work will be needed to define the link between CRY1/STK11 
and metformin-driven AMPK activation in immune cells. Protein expression analysis will 
be required to support our gene expression data. Overall, these findings initiate our 
understanding of how AMPK activation and changes in cellular metabolism activate 
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pathways leading to cytokine secretion by immune cells. Further study of the downstream 
effects of metformin and how it may change inflammatory cytokine profiles will 
strengthen the evidence identifying metformin as a viable preventative therapy for 
prediabetic patients.  
  x
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INTRODUCTION 
 Type 2 Diabetes Mellitus (T2D) is a metabolic disease that is a significant and growing 
health problem throughout many populations; it accounts for the majority of Diabetes 
Mellitus cases (>85%) in the United States [1], and is predicted to reach 552 million 
diagnoses by 2030 [2]. Given that incidence of obesity, the major risk factor for T2D, 
continues to rise globally in children, T2D is no longer considered an illness with a 
distinct onset in adulthood. The increased incidence of T2D across the age spectrum 
makes preventive measures for this disease a top healthcare priority.  
 T2D is an extension of Metabolic Syndrome, the name for a group of metabolic risk 
factors that raises the chance for developing T2D, heart disease, stroke, and other serious 
health problems [3]. Metabolic syndrome is defined by the presence of three of the 
following risk factors: abdominal obesity, high triglyceride level, low HDL cholesterol 
level, high blood pressure, and high fasting blood glucose [3]. High fasting blood glucose 
and abdominal obesity, accompanied by chronic inflammation, are key contributors to 
insulin resistance, which along with pancreatic beta cell dysfunction defines T2D [4].  
 Physiological Changes in T2D 
Insulin is a hormone that plays a major role in metabolism. Insulin stimulates liver, fat, 
and muscle cells to absorb glucose from the blood and store excess glucose as glycogen. 
After ingesting a meal, increased blood glucose levels signal to the beta cells in the 
pancreas to release insulin, leading to glucose uptake in various tissues and overall 
glucose homeostasis [5]. Insulin resistance develops when the liver, fat, and muscle cells 
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do not properly respond to this hormone, leading to the inefficient removal of glucose 
from the bloodstream. The beta cells must work harder to produce more insulin to keep 
up with the increased demand. Over time, these beta cells burn out and excess glucose 
builds up in the bloodstream [5]. In contrast to this classical model for T2D etiology, 
other lines of evidence point to the possibility that hyperinsulinemia due to beta cell 
dysfunction occurs prior to insulin resistance [6,7]. Regardless of the initiating factor for 
T2D, the resulting chronic high blood glucose can lead to nerve and blood vessel damage, 
and the development of health complications common with sub-optimally controlled 
diabetic patients such as kidney failure, heart disease, stroke, and lower-limb amputations 
[5].  
 Chronic inflammation plays a pivotal role in the onset of diabetes through the 
combination of glucose intolerance with cytokine production, leading to systematic 
insulin resistance [9]. The production of pro-inflammatory cytokines such as MCP-1 and 
TNFα in pathogenic central adipose tissue [8], signal and recruit immune cells leading to 
the activation of intracellular pathways involving the systematic inflammatory response. 
Numerous animal model studies and human associations have shown that inflammation 
promotes the transition from obese and metabolically health to obese and insulin resistant 
[10,11]. 
 Studies suggest the expression of an inflammatory T cell signature produced by a specific 
cell subset, Th17 cells, may promote the development of obesity-associated T2D [12]. 
Work from our lab demonstrated Th17 cytokine profiles derived from multivariate 
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analytical approaches predict T2D status of the sample donor with >85% accuracy, 
revolutionizing our ideas of the relationship between T cell inflammation and T2D 
pathogenesis. A shift in such T cell cytokine profiles may either promote or protect 
against obesity-associated insulin resistance [9]. Further work is ongoing to examine the 
specific mechanisms that link chronic T cell inflammation to the onset of T2D, and to 
identify therapeutic interventions that may help to shift from pro-inflammation to anti-
inflammatory cytokine profiles.  
 Treatment for T2D 
Current treatments for T2D involve changing diet and exercising habits to maintain a 
healthier lifestyle and decrease obesity and obesity-associated chronic inflammation. In 
some cases, diet and exercise is insufficient for reversing the effects of insulin resistance 
and medication must be prescribed. The main goal of these T2D treatments is to 
normalize blood glucose and increase insulin sensitivity in the body [13,14] In cases 
where the pancreatic beta cells can no longer produce enough insulin synthetic insulin 
must be injected regularly to stabilize blood glucose levels [13]. 
 There are many types of oral medications available for treatment of T2D, but the most 
commonly used treatments are sulfonylureas, DDP-4 Inhibitors, and biguanides [15]. 
Sulfonylureas stimulate insulin secretion from the pancreatic beta cells. DDP-4 inhibitors 
prevent breakdown of GLP-1, a naturally occurring compound that aids in reducing blood 
glucose levels in the body. Biguanides decrease glucose production by the liver and 
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increase insulin sensitivity in muscle tissue [15]. One of the most well-known and highly 
used drugs to treat diabetes is a biguanide derivative metformin.  
 Metformin, in conjunction with lifestyle modification, is considered the first-line 
recommendation for treating T2D. Clinical studies such as the UK Prospective Diabetes 
Study (UKPDS) have reported that metformin is associated with less weight gain, 
decreased risk of diabetes-related health problems in overweight diabetic patients, and 
fewer hypoglycemic episodes when compared to insulin or other diabetic oral 
medications [16]. Metformin may also have beneficial effects against cardiovascular 
mortality and various cancers [17].  
 The main actions of metformin include the suppression of liver glucose production and 
increased glucose utilization. However, the full range of mechanisms of action remains 
uncertain. The activation of AMPK, a well-known cellular energy sensor targeted by 
metformin, is intimately associated with the pleiotropic effects of metformin [16]. 
However, there is evidence that AMPK activation is a secondary effect to metformin, as 
its primary effect may be to inhibit of mitochondrial respiratory-chain complex 1; this 
inhibition would flux cell energy status, triggering the activation and downstream effects 
of AMPK [18]. Nevertheless, it is well documented that the activation of AMPK induces 
various changes including inhibition of glucose, lipid, and protein synthesis, along with 
stimulation of fatty acid oxidation and glucose uptake. These changes result in beneficial 
outcomes on insulin resistance and ultimately, normalization of blood glucose levels [19].  
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Preventing the Transition from Prediabetes to Type 2 Diabetes  
In addition to the rise in incidence in T2D, prediabetes, a precursor to T2D, is becoming 
more prevalent. Prediabetes is a condition where blood glucose levels are higher than 
normal but are under the threshold determined by the American Diabetes Association for 
a diabetes diagnosis. The U.S. Department of Health and Human Services estimates that 
one in four U.S. adults 20 years or older have prediabetes. If no steps are taken to prevent 
or delay further symptom progression, these individuals are likely to develop T2D within 
10 years [20].  
 The Diabetes Prevention Program (DPP) was a major study involving multiple clinical 
centers around the United States designed to investigate whether modest weight loss from 
change in diet and increased physical activity or treatment with metformin would prevent 
or delay in onset of T2D in study participants with prediabetes. The DDP showed that 
weight loss through dietary changes and increased physical activity impacted disease 
risk; participants who lost a modest amount of weight reduced their risk of developing 
diabetes by 71 percent over 3 years [20]. While taking metformin less dramatically 
reduced risk i.e. 31 percent, these results definitely gave support to the idea of taking 
metformin in conjunction with lifestyle modification as a preventative measure to delay 
the onset of T2D. Furthermore, the potential anti-inflammatory and protective properties 
of metformin against diabetic complications and insulin resistance signify more research 
needs to be done to understand effects of this treatment, which is FDA-approved to treat 
T2D, but not prediabetes. Therefore, it is logical as well as pertinent to generate data 
promoting metformin use as an off-label preventative drug for T2D.  
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 Goals of The Thesis 
Understanding the impact of metformin on chronic inflammation is critical to examine 
how the amelioration of the inflammatory response may aid in the protection against 
insulin resistance and T2D. In this study, I aimed to investigate the effects of metformin 
on immune cell function in prediabetes patients through preliminary gene expression 
analysis. I hypothesized that metformin would improve immune cell function by 
modulating genes in the AMPK pathway. The long-term goal of this study is to assess 
how metformin affects gene expression in the AMPK pathway, and how these changes in 
gene expression lead to a shift in cytokine secretion in immune cells. The objectives of 
my thesis are as follows: 
1. Conduct a preliminary study where prediabetes patients are prescribed metformin 
and collect blood samples at baseline and 3 months after start of metformin 
treatment. 
2. Isolate PBMCs and treat with CpG, anti-CD3/CD28, and LPS to stimulate B cells, 
T cells, and Myeloid cells in the samples, respectively.  
3. Run qRT-PCR on subset of cells to test changes in PBMCs from pre- and post-
metformin samples to determine if metformin treatment leads to any changes in 
gene expression in the AMPK pathway. 
4. Use preliminary results from subset data to generate human gene-specific primers 
and run qRT-PCR on entire dataset. 
5. Analyze qRT-PCR data to determine if same genes had similar change in 
expression across all stimulated cell subsets. 
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METHODS 
 We used the EPIC systems database to screen and recruit subjects with appointments 
scheduled at the Nutrition and Weight Management Center at Boston Medical Center 
from September 2015 through October 2016. Eligibility criteria for the study included 
BMI  30, prediabetes as indicated by and an A1C being between 5.7-6.4%, no 
medications affecting inflammation or blood glucose regulation, and no cancer or other 
serious health issues. Upon obtaining informed consent, we collected 60ml of blood 
(using six 10ml Acid-Citrate-Dextrose solution tubes) from each patient at the 
phlebotomy suite. Blood draw occurred when the patient was initially prescribed oral 
metformin (500mg twice/day), then again three months after metformin initiation. Figure 
1 depicts the flow of clinical set up for the study:  
 
Figure 1. Schematic Flow of Clinical Set Up for Study. A total of 49 pre-metformin samples and 13 post-metformin samples were collected. n = 49 subjects. 
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A single-step Ficoll gradient was used to separate and extract the immune cell-containing 
buffy coat needed for analysis (Figure 2). Plasma was also collected and archived for 
future study. For this step, three 50ml conical tubes were filled with 20ml of room 
temperature PBS and three 50ml conical tubes were filled with 15ml of Ficoll. The blood 
sample was diluted into the PBS (2 blood tubes per 50ml conical tube). The diluted 
mixture was then slowly layered onto the Ficoll and spun at 800 rcf, with brake off, for 
25 minutes. 
 
Figure 2. Isolation and Archiving of PBMCs. A total of 49 pre-metformin samples and 13 post-metformin samples were processed and archived. n = 49 subjects. 
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The buffy coat, which lay at the interface between the Ficoll and the PBS/blood mixture, 
was transferred to a clean 50ml centrifuge tube and the remaining volume was filled with 
sterile Buffer 1 (FACS buffer- PBS +BSA). Tubes were spun at 550 rpm, with brake on, 
for 10 minutes. The liquid was then aspirated from the cell pellet, and the pellet was 
resuspended in 6mls of Red Blood Cell Lysis Buffer prior to incubation for 6 minutes at 
37 C, 5% CO2. Buffer 1 was then added to bring volume to 50ml. Ten ul was removed 
for cell counting and the remainder was spun at 550 rpm, with brake off, for 10 minutes. 
During the last centrifugation, cells were counted to prepare freezing media (90% FBS + 
%10 DMSO) for 1ml of freezing media per 10x10^6 cells. Tubes were labeled 
appropriately to freeze down 10x10^6 cells/ml aliquots and 1-5x10^6 cell/500ul aliquots. 
The liquid was aspirated and the cells were resuspended in freezing media; aliquots were 
stored in cryovials and placed in a Mr. Frosty apparatus overnight in -80 C. Cells were 
then transferred to liquid nitrogen for long-term storage.   
 Human PBMCs from the 13 subjects with both a pre- and post-metformin sample were 
thawed quickly in a 37 C water bath, and transferred into a 15ml conical tube that 
contained 10ml cold RPMI media. Ten ul cells were removed for counting, and the 
remaining cells were centrifuged at 550 rcf, with brake off, for 10 minutes. After 
aspiration of the liquid, cells were resuspended at 700,000 cells per 1ml of media. The 
cells were then seeded onto a 24 well plate, 1 ml per well, with the following 
experimental layout for each blood sample: 
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24-hour 
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stimulated 
 
24-hour 
LPS 
 
24-hour  
CpG 
 
24-hour 
CD3/CD28  
40-hour  
non-
stimulated 
 
40-hour 
CD3/CD28 
 
      Figure 3. Experimental Layout for Activation of PBMCs. A total of 13 pre-metformin samples and 13 post-metformin samples were activated according to experimental layout. n = 13 subjects.  
 While the cells equilibrated in the incubator, three activation stimuli, all of which 
primarily activate different immune cell subsets within the complex cellular mixture of 
PBMCs, were prepared: LPS for activation of myeloid cells, CpG ODN 2006 for 
activation of B cells, and anti-CD3/CD28 Dynabeads for activation of T cells. To activate 
T cells, Dynabeads were vortexed, pipetted up and down to thoroughly mix, and 
transferred to a 1.5ml Eppendorf tube filled with 1ml of Buffer 1. Tubes were then placed 
against a magnet for 2-3 minutes. After supernatant was pipetted from the beads, the tube 
was removed and the beads were resuspended in original volume of RPMI media. The 
beads were then added to the PBMC-containing wells at 15ul to activate primarily T 
cells. LPS was used at 6ul per well, at a concentration of 10ng/ml to activate monocytes. 
CpG was used at 6ul per well, at a concentration of 250ng/ml to activate primarily B 
cells. RPMI media was then added at 485ul to the Dynabead wells, and 494ul to the LPS 
and CpG containing wells, to bring each well to a total volume of 1.5ml, mixing slowly. 
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The plate was incubated with stimuli for 24 or 40 hours at 37 C, 5% CO2. We 
transferred the supernatants from the 24-hour stimulated culture to 1.5ml Eppendorf 
tubes, spun down the cells at 600 rcf, then transferred the supernatants equally between 
two 1.5ml Eppendorf tubes, per condition. The cell pellets left in the original Eppendorf 
tubes were quickly submerged in liquid nitrogen and stored at -80 C. The supernatants 
collected after the 40-hour stimulation, were processed identically. Figure 3 shows an 
overview of this PBMC activation process: 
 
Figure 4. Overview of PBMC Activation. After activation of the 13 pre- and 13 post-metformin samples, the cells and supernatants were collected and stored until further analysis. n = 13 subjects.  
 
Prepare Cells
• Thaw PBMCs and prepare in RPMI media• Seed 6 wells in 24 well plate with 1ml of cells (per sample) 
Prepare Stimulus
• Prepare the 3 stimulus conditions• Add stimulus and additional RPMI to appropriate wells to total volume of 1.5ml
Incubation
• Incubate for 24 or 40 hours
Transfer and Store
• Transfer the supernatants and store at -80 C• Flash freeze cell pellets in liquid nitrogen and store at -80 C  
 12 
Cell pellets from all 24-hour and 40-hour conditions were thawed to isolate RNA and 
remove genomic DNA using Qiagen RNeasy Micro Kit. Thermo Scientific NanoDrop 
Spectrophotometer was used to assess quantity and purity of RNA. RNA concentrations 
were calculated and reverse transcribed using the Thermofisher High-Capacity RNA-to-
cDNA Kit, producing cDNA. Fifty ng of cDNA from the 40-hour CD3/CD28 activated 
PBMCs of 4 randomly chosen subjects’ pre- and post-metformin samples were run on 
SABiosciences Human AMPK Signaling qRT-PCR Array. Qiagen RT2 Profiler qRT-
PCR Array Data Analysis version 3.5 was used on the subset data to analyze qRT-PCR 
array results and used an unpaired student’s t-test to evaluate significant changes in gene 
expression.  
 We used the data from the analysis software to create a volcano plot, which I used to 
broadly investigate candidate targets possibly modulated by metformin. The program 
calculated the fold change and p-values (unpaired student’s t-test; program only runs 
unpaired) from the average relative expression of genes of the 40-hour CD3/CD28 
activated PBMCs in the pre- to post-metformin samples. We normalized gene expression 
to the average of three housekeeping genes: RPLP0, HPRT1, and -actin. Six target 
genes were chosen for independent validation by identifying the data points on the 
volcano plot that had the greatest difference in log2 (fold change) or –log (p-value). I used 
individual Ct values of these six target genes to calculate relative gene expression and 
fold change of each gene among the 4 individual subjects. Relative gene expression and 
fold change was normalized to housekeeping gene RPLP0. A paired student’s t-test was 
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utilized to examine if individual subjects showed any statistically significant changes in 
normalized delta Ct values or relative gene expression.  
 To validate and expand the AMPK array-based studies, I first used the NCBI Primer-
Blast tool to design human gene-specific primers from the 6 most metformin-sensitive 
targets following anti-CD3/CD28 stimulation in the AMPK plate-based analysis. I then 
used these primers and RT² SYBR Green qRT-PCR Mastermix to run qRT-PCR on 
cDNA from all the activation conditions of the 13 pre- and 13 post-metformin samples 
(Table 3). Five ng of cDNA were used per reaction. qRT-PCR was performed in 
technical duplicates and the real-time data was normalized using the geNorm algorithm 
[21] to RPLP0 and HPRT1 expression. Graph Pad Prism was utilized to create graphs 
comparing log-transformed relative gene expression of pre- and post-metformin samples 
in all conditions. All qRT-PCR reactions were run on an Applied Biosystems 7900HT 
Fast Real-Time qPCR System for 40 cycles. All kits were used according to the 
manufacturers’ protocols. 
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RESULTS 
 This study included a total of 13 subjects, 12 female and 1 male. The median age of the 
subjects was 47 (33-55) years and the majority of the sample population was African 
American (69.2%). Table 1 includes measurements for BMI, fasting blood glucose, blood 
pressure, HDL cholesterol, LDL cholesterol, and TG levels from the study participants: 
       Table 1. Baseline Characteristics of Study Subjects. n = 13 subjects. Age, years, median (range) 47 (33-55) Sex   Female  12 Male 1 Race   African American 9 Haitian 1 Hispanic 1 White/non-Hispanic 2   BMI kg/m2, mean (range) 38.6 (30.7-59.6) Fasting Blood Glucose mg/dL, median (range) 102.5 (86.0 -116.0) 
Blood Pressure  SBP mmHg, median (range) 125 (104-152) DBP mmHg, median (range) 82 (68-90) A1C %, median (range) 5.8 (5.7-6.5) Lipids  TG mg/dL, mean (range) 122.8 (56.0 – 320.0) HDL mg/dL, median (range) 42.5 (33.0 – 71.0) LDL mg/dL, median (range) 112.5 (73.0-155.0)  BMI ranged from 30.7 to 59.6 kg/m2 and A1C ranged from 5.7-6.5%, indicating all but 
one of the participants were categorized as obese with prediabetes per the NIH guidelines 
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[5]. One subject had an A1C of 6.5%, which is considered the diagnostic point for T2D; 
however, this subject did not have historical results of 6.5% or higher nor was diagnosed 
with T2D at time of study. Therefore, the subject was included in this analysis. Fasting 
blood glucose levels between 100 and 125 mg/dL indicates prediabetes [5]. This cohort 
averaged at 102.5 (86-116) mg/dL, indicating certain subjects had fasting blood glucose 
levels in the normal range and others in the prediabetes range. Blood pressure of 
individuals ranged from normal (below 120/80 mmHg) to hypertensive (above 126/90 
mmHg) [5], with median blood pressure being 125.0/82.0 mmHg.  
 Table 2. Comparison of Subjects’ BMI Before and After Metformin. Values are the mean BMI of subjects at baseline and after 3 months taking metformin. A paired student’s t-test was used to calculate significance. Significance was accepted at p  0.05. SD = standard deviation. SEM = standard error of mean. n = 13 subjects. BMI Pre Metformin BMI Post Metformin p-value kg/m2, mean         SD      SEM kg/m2, mean        SD      SEM 
38.6  8.92 2.48 36.9  8.93 2.48 0.0055 
  BMI change post-metformin compared to baseline was highly statistically significant (p = 
.0055; n = 13, paired t test on BMI data collected from subjects charts) (Table 2). The 
mean of BMI before the start of metformin was 38.6 (8.92) and mean of BMI after 3 
months of taking metformin was 36.9 (8.93). This result indicated that there was an 
average weight loss of 4.5 kg or 10lbs over the 3 months subjects took metformin.  
  
 
 
 16 
qRT-PCR Data Analysis Leading to Design of Gene Primers 
Qiagen RT2 Profiler qRT-PCR Array Data Analysis version 3.5 was used to assess 
mRNA expression in the 40 –hour anti-CD3/CD28-activated PBMCs of a subset of 4 
subjects pre and post metformin. The program calculated the fold change and p-values 
(unpaired student’s t-test) from the relative expression of genes in the pre- to post-
metformin samples. We generated a volcano plot using log2 (fold change) on the x-axis 
and –log (p-value) on the y-axis (Figure 5). Each data point represents the average of the 
4 subjects’ change in gene expression from baseline to 3 months after taking metformin. 
The vertical red dotted lines denote fold changes of 2. The horizontal red dotted line 
denotes a p-value of 0.05. Using this plot, I evaluated gene candidates that could be 
modulated by metformin. 
 I assessed the genes based off their log 2 (fold change) and –log (p-value). SLC2A4, 
LIPE, INSR, CRY1, GAPDH, and STK11 had the greatest log 2 (fold change) and –log (p-
value). I also used published work to evaluate the biological relationship of each of these 
genes to cellular metabolism (Table 3). SLC2A4, LIPE, and INSR are associated with 
glucose and fatty acid metabolism, and CRY1 is a gene associated with circadian rhythm. 
All four of these genes had negative fold changes in gene expression (i.e. were down 
regulated) in response to metformin intervention. STK11, an mTOR regulator gene, and 
GAPDH, a glucose metabolism gene, increased in expression in response to metformin 
intervention. Due to the highest fold change in these six targets I chose to validate 
potential changes in gene expression in the paired anti-CD3/CD28 stimulated samples 
from 4 subjects to the total group of 13 subjects and to all three stimulation conditions.  
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 Figure 5. Volcano Plot: Pre vs. Post Metformin in Prediabetes. The volcano plot visualizes our data to quickly identify variation in the relative gene expression in 40-hour CD3/CD28 activated PBMCs. Log 2 (fold change) is on the x-axis and –log (p-value) is on the y-axis. Fold change = ((2^-(post-metformin Ct – HKG Ct))/(2^-(pre-metformin Ct – HKG Ct))). HKG= an average of HPRT1, RPLP0, and -actin. An unpaired student’s t-test was used to compare the log-transformed relative gene expression between pre- and post- metformin samples. Significance was accepted at p  0.05. The vertical red dotted lines denote fold changes of 2. The horizontal red dotted line denotes a p-value of 0.05. Red dots indicate up-regulation of gene expression. Green dots indicate down-regulation of gene expression. n = 4 subjects.       
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  Table 3. Metabolic Effects of Target Genes.  Name of Target Gene Protein/ Metabolic Association 
SLC2A4 GLUT4 Transporter/Glucose Metabolism 
LIPE HSL/Fatty Acid Metabolism/Lipolysis 
INSR Insulin Receptor CRY1 Circadian Regulation GAPDH Glucose Metabolism STK11 mTOR Signaling   
To validate outcomes from the limited n = 4 assayed in the array plates, I first created 
qRT-PCR primers for the six targets that were chosen from the qRT-PCR array to test 
under standard qRT-PCR conditions. In contrast to the array plate software, which 
analyzes samples as if unpaired, my traditional qRT-PCR was appropriately analyzed 
with paired tests that add statistical power. Table 4 shows the mean, SD, SEM, and p-
values from comparing the delta Ct values, the relative expression, and the log 
transformed relative expression of each of the 6 target genes between the 40-hour 
CD3/CD28 activated pre- and post-metformin samples. Results for CRY1 showed a 
significant decrease in delta Ct value with p = 0.03 (n = 4, paired t test) and a significant 
decrease in relative gene expression with p = 0.03 (n = 4, paired t test on log transformed 
data).  The rest of the genes analyzed did not show any significant change in expression. 
Analysis comparing the relative gene expression per individual subject is in Appendix A.  
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Table 4. Comparison of Ct Values and Relative Gene Expression in the 40-hour anti-CD3/CD28 Activated PBMCs of 4 Prediabetic Subjects. Housekeeping gene used was RPLP0. Ct values = cycle threshold when gene expression was detected. Delta Ct Values = (Ct gene of interest – Ct RPLP0) per condition. Relative Gene Expression = (2^-(Ct gene of interest – Ct RPLP0)) per condition. Log-Transformed Gene Expression = log (2^-(Ct gene of interest – Ct RPLP0)) per condition. I used a paired student’s t-test to calculate significance. Significance was accepted at p  0.05, indicated in red. SD = standard deviation. SEM = Standard Error of Mean. n = 4 subjects. 
Gene Pre-Metformin Post-Metformin  Ct Values Mean SD SEM Mean SD SEM p- value CRY1 25.61 0.28 0.14 25.64 0.07 0.03 0.83 INSR 29.75 0.51 0.25 29.92 0.42 0.21 0.64 LIPE 25.51 0.37 0.19 25.87 0.83 0.42 0.44 SLC2A4 31.64 0.25 0.13 32.43 1.07 0.53 0.30 STK11 27.62 0.66 0.33 26.67 0.25 0.13 0.11 GAPDH 19.66 0.72 0.36 18.99 0.28 0.14 0.11 RPLP0        Delta Ct Values Mean SD SEM Mean SD SEM p- value CRY1 6.48 0.40 0.20 6.89 0.26 0.13 0.03 INSR 10.62 0.18 0.09 11.17 0.53 0.27 0.19 LIPE 6.37 0.70 0.35 7.12 0.70 0.35 0.29 SLC2A4 12.51 0.59 0.29 13.69 1.29 0.65 0.17 STK11 8.48 0.55 0.28 7.92 0.25 0.12 0.16 GAPDH 0.53 0.28 0.14 0.24 0.10 0.05 0.23 Relative Expression values are x10-2 Mean SD SEM Mean SD SEM p- value CRY1 1.15 0.32 0.16 0.85 0.15 0.07 0.07 INSR 0.06 0.008 0.004 0.05 0.02 0.009 0.22 LIPE 1.30 0.50 0.25 0.77 0.29 0.15 0.21 SLC2A4 0.02 0.008 0.004 0.01 0.01 0.005 0.33 STK11 0.29 0.09 0.05 0.42 0.07 0.03 0.11 GAPDH 70.35 13.12 6.56 84.65 5.62 2.81 0.22 Log-Transformed Relative Expression 
Mean SD SEM Mean SD SEM p- value 
CRY1 -1.95 0.12 0.06 -2.07 0.08 0.04 0.03 INSR -3.20 0.05 0.03 -3.36 0.16 0.08 0.19 LIPE -1.92 0.21 0.11 -2.14 0.21 0.10 0.29 SLC2A4 -3.77 0.18 0.09 -4.12 0.39 0.19 0.17 STK11 -2.55 0.17 0.08 -2.38 0.07 0.04 0.16 GAPDH -0.16 0.08 0.04 -0.07 0.03 0.01 0.22 
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The designed primers for SLC2A4, LIPE, INSR, CRY1, GAPDH, and STK11 are in Table 
5. I utilized NCBI Primer-Blast tool to find primers that had the smallest amount of 
nucleotides per primer without losing product specificity. The majority of the primers had 
a product length of fewer than 100 nucleotides, except GAPDH, which needed to be 113 
nucleotides to ensure specificity. The melting temperatures for both the forward and 
reverse primer reactions, Tm F and Tm R, ranged from 57.27 °C – 60.39 °C (difference of 
3.12 °C) and 58.30 °C – 60.25 °C (difference of 1.95 °C), respectively. The percentages 
of Guanine-Cytosine content (% GC) in both the forward and reverse primer groups were 
kept between 50 – 60 %. 
 
Table 5. Designed Target Primers.  
Target 
Gene 
Forward (5’ -> 
3’)  
Reverse (5’ -
> 3’) 
Product 
Length 
Tm F** 
(°C) 
Tm R** 
(°C) 
% 
GC* F 
% 
GC* R 
SLC2A4 GTTCTTTCATC-
TTCGCCGCC 
TTCCCCATCTT
-CGGAGCCTA 
90 59.9 60.03 55 55 
LIPE GTGCTAGGCA-
CATAGCCTCC 
AGCTGGCCCC-
CACTAAGTAA 
84 60.25 60.25 60 55 
INSR GACGTCCCGT-
CAAATATTGC 
GATGAGGGGG
-CCGATGATAA 
45 57.27 59.02 50 55 
CRY1 CCTCCAATGT-
GGGCATCAAC 
CTGAAGCAAA-
AATCGCCACC 
41 59.18 58.30 55 50 
GAPDH CTCCTGTTCG-
ACAGTCAGCC 
GCGCCCAATA-
CGACCAAATC 
113 60.39 59.97 60 55 
STK11 GCAGGAGTGT-
GCGGTCAATA 
CGATGGCGTT-
TCTCGTGTTT 
61 60.39 59.49 55 50 
*GC stands for nucleotides Guanine & Cytosine; ** Tm F and Tm R stand for Melting Temperature of Forward Reaction (5’ -> 3’) primer and Reverse Reaction (5’ -> 3’) primer, respectively.    
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qRT-PCR was run in technical duplicate with the human gene-specific primers. The real-
time data was normalized using the geNorm algorithm [21] to RPLP0 and HPRT1 
expression. We used Graph Pad Prism to create graphs with the qRT-PCR data to 
compare the relative expression value of the six genes in all conditions between 12 pre- 
and 12 post- metformin samples (Appendix B). Although qRT-PCR was done for all 13 
subjects, during analysis there was a subject whose gene expression exceeded 2 SD from 
the mean in each group. Therefore, the subject was excluded from analysis. There were 
three statistically significant changes of relative gene expression from pre- to post-
metformin; the decrease in expression of STK11 in the 24-hour non-stimulated condition 
(p = .0078, n =12, paired t test on log transformed data), the decrease in expression of 
CRY1 in the 24-hour CD3/CD28 activated condition (p = .043, n = 12, paired t test on log 
transformed data), and the increase in expression of SLC2A4 in the 24-hour CpG 
activated condition (p = .0179, n = 12, paired t test on log transformed data). We noted 
that 6 of the subjects in the 24-hour CpG activated condition had undetectable values or 
very low, likely unreliable values for SLC2A4 expression so we omitted those from the 
plot shown in Figure 6 (n = 6). However, consistent with the conclusion that metformin 
increased expression, we noted that that GLUT4 mRNA was not detected in 6 subjects 
prior to metformin treatment. Yet, 4 of these 6 subjects did show detectable levels of 
GLUT mRNA 3 months after starting metformin treatment. 
 22 
  Figure 6. Relative Expression of GLUT-4 mRNA. Analysis is only on pairs of data in which SLC2A4 was detectable in both pre- and post-metformin samples. A paired student’s t-test was used to compare the average log-transformed relative gene expression in 6 pre- and 6 post-metformin samples from 24-hour CpG activated PBMCs. Significance was accepted at p  0.05. p = 0.08. n = 6 subjects.       
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DISCUSSION 
 I performed gene expression analyses on PBMCs from prediabetes subjects to begin 
understanding how metformin treatment delayed fulminant type 2 diabetes in prediabetes, 
as published in the Diabetes Prevention Program studies [20]. Our first finding was an 
expected change of BMI in the 13 subjects from baseline to the 3-months after initiation 
of metformin therapy. The average weight loss among the subjects during the 3 months 
they were taking metformin was 4.5 kg. The decrease in BMI was expected given that 
metformin has been associated with weight loss [20]. While other (non-DPP) metformin 
studies haven’t shown robust data regarding expected weight loss, I speculate there was a 
motivational aspect for metformin-associated weight loss in our subject cohort. The 
clinicians at the Nutrition and Weight Management Center at Boston Medical Center 
general prescribed a weight loss diet or exercise regimen that would synergize with 
metformin treatment. However, we did not collect data on glycemic control, physical 
activity, or whether the Nutrition and Weight Management Center at Boston Medical 
Center offered diet or exercise counseling to the subjects to comment on this possibility. 
Therefore, more systematic research is warranted to examine if metformin has such a 
robust effect on weight. 
 The preliminary subset data of n = 4 from the AMPK qRT-PCR array on 40-hour anti-
CD3/CD28 stimulated PBMCs showed that there was a significant decrease in expression 
of CRY1, a circadian function gene, from pre- to post-metformin conditions (p = .03, n = 
4, paired t test on log transformed averaged data). The other genes did not show 
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significant changes. In the individual analysis of the n =4 data, there was a lot of 
variability among the other genes, indicating these preliminary results were most like 
skewed due to a small sample size. Fold change patterns from the individual analysis 
depicted in Appendix A showed that while 3 out of 4 subjects had decreased gene 
expression for INSR (0.49, 0.46, and 0.81), and SLC2A4 (0.23, 0.22, and 0.49), one 
subject had an increased fold change for both of these genes (1.20 and 1.52, respectively). 
For LIPE, 3 out of 4 subjects showed a decreased fold-change (0.73, 0.21, 0.59), whereas 
one subject, different from the previous comparison, had an increased fold-change (1.41). 
One of the effects of metformin is to activate the AMPK pathway, which leads to the 
decrease in glycolytic metabolism and an increase in fatty acid oxidation. We would have 
expected an increase in LIPE, a lipolysis gene, and a decrease in INSR, an insulin 
receptor gene and SLC2A4, a GLUT4 transporter gene. With n = 4, we were unable to 
fully support the evidence for this pathway. These results were additional motivation to 
run qRT-PCR on n = 13 with the generated human gene-specific primers.  
 With the qRT-PCR data from all stimulation conditions and n =13 subjects, I found a 
significant decrease in expression of CRY1 between pre- and post-metformin in 24-hour 
anti-CD3/CD28 activated PBMCs (p = .04, n = 12, paired t test on log transformed data). 
This was an interesting result because there was no longer a statistical significant change 
in CRY1 in the 40-hour CD3/CD28 activated PBMCs. Nevertheless, the trend indicating 
that metformin may decrease CRY1 gene expression supports growing evidence that that 
circadian rhythms affect the immune system. One study showed that autonomous 
circadian clockwork exists in immunological tissues, including peritoneal macrophages 
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[25]. Another study had supporting evidence that CRY1 influences oscillatory cytokine 
secretion [26]. Therefore, it may be possible that a disruption of CRY1 expression may 
lead to dysfunction of cytokine secretion or a shift in cytokine profiles. It may be 
worthwhile to investigate further the effects of metformin on CRY1 and how it may 
regulate pro-inflammatory cytokine expression.   
 One of the other genes that showed a significant change in the qRT-PCR data involving 
all conditions and 13 subjects was STK11: qRT-PCR analysis showed that compared to 
baseline, the post-metformin 24-hour incubated cells decreased gene expression. These 
results were shown only in the non-stimulated cells, which raised the question of why this 
trend didn’t occur in the other conditions. STK11 is an mTOR inhibitor gene that leads to 
the inhibition of protein synthesis [22]. The decreased gene expression of STK11 in the 
non-stimulated PBMCs but not in the LPS-, CpG-, or anti-CD3/CD28 conditions may 
indicate that this is an effect from another subset of cells that weren’t stimulated in the 
current study design. Alternatively, this effect may be a supraphysiological expression of 
STK11 in the non-stimulated cells responding to in-vitro conditions. Additional research 
is needed to see if this result is reproducible. If these results can be replicated, the next 
step would be to examine mechanisms and cells that explain decreased expression of an 
mTOR inhibitor gene through metformin-driven activation of AMPK or other targets. 
 One intriguing result of this study was the positive fold change in the expression of 
SLC2A4 in the 24-hour CpG activated PBMCs. SLC2A4 encodes GLUT4, a glucose 
transporter found in insulin-dependent tissues such as muscle and adipose tissue [23]. 
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Only one report shows evidence of GLUT4 transporters on the plasma membranes of 
immune cells, which are not considered to be insulin-dependent cells [24]. The authors of 
the study indicated that in the resting state B cells and monocytes expressed GLUT4; 
however, in the activated state monocytes, B cells and T cells increased GLUT4 
expression. Our data shows that GLUT4 mRNA was detected in all PBMC conditions, 
supporting the evidence that there is GLUT4 gene expression in immune cells, although 
our approach did not give information on specific GLUT4+ PBMC cell types. In 
addition, our data shows that there was increased gene expression in CpG activated 
immune cells (B cells) in post-metformin samples. Protein expression analysis would be 
critical to examine if GLUT4 mRNA levels correlate to protein expression in immune 
cells.  
 Future work could examine whether the increased expression of SLC2A4 is due to 
metformin or from possible increased levels of exercise from the study subjects per 
speculation over weight loss mechanisms above. Exercise has shown to increase GLUT4 
expression [28, 29]. Depending on when the post-metformin samples were collected from 
our subjects, whether or not they just exercised or have an increase in intense physical 
activity, for example, due to a difficult commute to the Medical Center, could have 
affected study results. Overall, we must investigate whether these results could be 
supporting evidence in regards to immune cells using GLUT4 transporters and 
furthermore, if metformin affects these mechanisms through the AMPK pathway.  
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In future studies, we would need to see if all our results could be replicated in a larger 
sample population. We would also need to confirm how the up- or down- regulation of 
these genes affects protein expression. In addition to evaluating target mRNA-encoded 
proteins in all samples, we will also analyze the secreted cytokines from the collected 
supernatants. These studies are ongoing.  
 Some limitations of this study include restriction of characteristic data of subjects and a 
small study population due to lack of post-metformin subject recall. We were able to 
obtain only BMI for comparison of baseline and follow up due to data input restrictions 
of the EPIC systems database. In future studies we should have approval to collect 
baseline and follow up data for blood pressure, lipid profiles, fasting blood glucose, and 
anthropometric data such as height and weight. Other useful information from the 
subjects would be physical activity changes and food diaries, whether the subjects were 
given diet or exercise advice, or went on a prescribed diet. In the current study we could 
only compare BMI, which is not a robust measurement for weight loss. In addition to 
collecting more clinical information and samples from subjects, our IRB should be 
changed so we may contact subjects prior to their follow up appointment. This would 
help to ensure subjects are still taking metformin as prescribed during the study. 
Furthermore, contacting subjects would allow us to encourage subjects to attend the 
follow up visit. Even though we had 49 baseline entries to study, we recalled only 13 
subjects post-metformin, i.e. only 26.5% of the cohort. 
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Finally, the longitudinal study assisted in increasing internal validity and statistical 
power. However, in future studies it may be helpful to, in addition to the pre- and post- 
metformin group, add a control group that is not on metformin or is taking a metformin 
placebo. The addition of this control group would help to account for environmental 
changes such as motivation following clinical counseling, weather, time of year, and 
possibly time of day (especially for analysis of CRY1, a circadian rhythm gene).  
 Nevertheless, these findings are a step towards understanding how metformin, likely 
AMPK activation, and changes in cellular energy metabolism may control the secretion 
of cytokines by immune cells. Previous studies have shown the change in cellular energy 
metabolism leads to amelioration of insulin resistance and pro-inflammatory cytokine 
profiles [27]; further study of the downstream effects of metformin with changes in 
inflammatory cytokine profiles may assist in identifying metformin as a viable 
preventative therapy for prediabetic patients. 
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APPENDIX A 
Comparison of Relative Gene Expression and Fold Change in 4 Prediabetic Subjects. Housekeeping gene used was RPLP0. PRE = pre-metformin, baseline. POST = post 3 months taking metformin. Delta Ct = (Ct gene of interest – Ct RPLP0). Relative Expression = 2^(-(Ct gene of interest – Ct RPLP0)) per condition. Fold change = (2^-(Post-Met Ct gene of interest – Post-Met Ct RPLP0))/(2^-(Pre-Met Ct gene of interest – Pre-Met Ct RPLP0)). A paired student’s t-test was used to compare relative gene expression of pre- and post-metformin samples. Significance was accepted at p  0.05. n = 4 subjects.  
Subject Gene PRE Delta Ct  
POST Delta Ct  
PRE Relative Expression (values are 10-2) 
POST Relative Expression (values are 10-2) 
Fold Change 
1 CRY1 6.33 6.68 1.24 0.97 0.79  INSR 10.70 10.44 0.06 0.07 1.20  LIPE 6.18 6.62 1.38 1.01 0.73  SLC2A4 12.47 11.87 0.02 0.03 1.52  STK11 8.30 7.82 0.32 0.44 1.40  GAPDH 0.85 0.14 55.46 90.75 1.64 2 CRY1 5.99 6.68 1.57 0.98 0.62  INSR 10.43 11.47 0.07 0.04 0.49  LIPE 5.86 8.15 1.72 0.35 0.21  SLC2A4 11.72 13.84 0.03 0.01 0.23  STK11 8.05 7.72 0.38 0.47 1.25  GAPDH 0.28 0.33 82.30 79.64 0.97 3 CRY1 6.77 7.21 0.92 0.68 0.74  INSR 10.51 11.65 0.07 0.03 0.46  LIPE 6.04 6.80 1.52 0.90 0.59  SLC2A4 12.74 14.90 0.01 0.00 0.22  STK11 9.29 7.86 0.16 0.43 2.70  GAPDH 0.66 0.18 63.22 88.11 1.39 4 CRY1 6.83 6.99 0.88 0.79 0.90  INSR 10.83 11.13 0.05 0.04 0.81  LIPE 7.40 6.91 0.59 0.83 1.41  SLC2A4 13.10 14.13 0.01 0.01 0.49  STK11 8.29 8.28 0.32 0.32 1.01  GAPDH 0.31 0.32 80.40 80.11 1.00         CRY1 INSR LIPE SLC2A4 STK11 GAPDH p-value .067 .224 .211 .331 .114 .224   
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APPENDIX B 
  Matrix Showing Change in Relative Expression of Six Genes in Multiple Conditions Pre- and Post- Metformin. Matrix includes log-transformed relative expression of six target genes in all conditions. A paired student’s t-test was used to compare average relative expression between 12 pre- and 12 post-metformin samples. Significance was accepted at p  0.05. Conditions with significant changes are boxed in red. NS = Non-stimulated. 24 = incubated for 24 hours. 40 = incubated for 40 hours. 1 subject as excluded from analysis due to gene expression values exceeding 2 SD from the mean. n = 12.            
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